Selective Androgen Receptor Modulators (SARMs) represent one of the most actively studied classes of compounds in modern pharmacological research. First developed in the late 1990s, these non-steroidal ligands selectively bind to androgen receptors in specific tissues, offering researchers a powerful tool for investigating androgen signaling pathways without the broad systemic effects associated with traditional anabolic agents. This guide provides an in-depth overview of SARMs, their mechanism of action, key compounds, and current research applications — strictly for research purposes only.
What Are SARMs?
SARMs are a class of therapeutic compounds with properties similar to anabolic steroids, but with reduced androgenic activity. Unlike traditional androgens that bind to androgen receptors (ARs) throughout the body, SARMs exhibit tissue-selective activation — meaning they can preferentially stimulate anabolic activity in certain tissues (such as muscle and bone) while minimizing effects in others (such as the prostate or sebaceous glands).
The term “selective” is the defining characteristic. While testosterone and its derivatives activate androgen receptors broadly, SARMs achieve their selectivity through several mechanisms:
- Tissue-specific co-regulator recruitment — SARMs induce unique conformational changes in the androgen receptor, leading to the recruitment of different co-activator and co-repressor proteins depending on the tissue type.
- Differential gene expression — The AR-SARM complex activates different gene transcription patterns compared to the AR-testosterone complex.
- Non-aromatizable structure — Most SARMs cannot be converted to estrogen by aromatase enzymes, eliminating estrogen-related secondary effects in research models.
- 5-alpha reductase resistance — SARMs are generally not substrates for 5-alpha reductase, the enzyme that converts testosterone to the more potent dihydrotestosterone (DHT).
Mechanism of Action
The androgen receptor is a member of the nuclear receptor superfamily — a class of intracellular transcription factors. When a SARM binds to the androgen receptor, it triggers a cascade of molecular events:
- Ligand binding — The SARM molecule enters the cell and binds to the ligand-binding domain (LBD) of the androgen receptor.
- Conformational change — Binding induces a specific three-dimensional shape change in the receptor. This conformation differs from what testosterone or DHT would produce, and this difference is the molecular basis of tissue selectivity.
- Nuclear translocation — The activated AR-SARM complex translocates from the cytoplasm into the cell nucleus.
- DNA binding — The complex binds to androgen response elements (AREs) on target genes.
- Selective transcription — Depending on the tissue and available co-regulators, specific genes are upregulated or downregulated — producing anabolic effects in muscle and bone tissue while demonstrating reduced activity in reproductive tissues.
This tissue-selective transcriptional activity is what distinguishes SARMs from conventional androgens and makes them valuable tools for studying the androgen receptor signaling pathway in controlled research environments.
Key SARM Compounds: Research Profiles
The following compounds represent the most extensively studied SARMs in current research literature. All compounds discussed are available from CertaPeptides for licensed research use, with purity verified through independent third-party testing.
Ostarine (MK-2866 / Enobosarm)
Ostarine is arguably the most widely studied SARM. Developed by GTx Inc., it has progressed furthest in clinical research among all SARMs, reaching Phase III trials for muscle wasting conditions. In preclinical research models, Ostarine has demonstrated dose-dependent increases in lean body mass with minimal prostate weight changes — a hallmark of androgen receptor selectivity. Its oral bioavailability and relatively long half-life (approximately 24 hours in research models) make it a practical compound for extended study protocols.
LGD-4033 (Ligandrol)
Developed by Ligand Pharmaceuticals, LGD-4033 is considered one of the most potent SARMs by binding affinity. Research has demonstrated that it has a high affinity for the androgen receptor (Ki of approximately 1 nM) with selectivity for muscle and bone over prostate tissue. Studies in research models have shown significant increases in lean mass even at very low doses, making it a useful compound for dose-response investigations. Its half-life of 24-36 hours supports once-daily research dosing protocols.
RAD-140 (Testolone)
RAD-140 was developed by Radius Health specifically for its high tissue selectivity. Preclinical research has shown an anabolic-to-androgenic ratio exceeding 90:1 in some models — compared to testosterone’s 1:1 ratio. This exceptional selectivity has generated interest for studying androgen receptor activity in neural tissues, where RAD-140 has demonstrated neuroprotective properties in cell culture models. It is also under investigation for its effects on lipid profiles in research settings.
MK-677 (Ibutamoren)
Technically classified as a growth hormone secretagogue rather than a SARM, MK-677 is frequently grouped with SARMs in the research community. It functions as an orally active ghrelin receptor agonist that stimulates growth hormone (GH) release from the pituitary gland. Research has shown sustained elevation of GH and IGF-1 levels without affecting cortisol in preclinical models. Its unique mechanism makes it a valuable tool for studying the GH/IGF-1 axis alongside androgen receptor modulation.
Andarine (S-4)
One of the earliest SARMs developed, Andarine was created by GTx Inc. It demonstrates partial agonist activity at the androgen receptor, making it useful for studying dose-response relationships and partial agonism in AR signaling. Research models have shown effects on bone mineral density and lean mass, with notable selectivity over reproductive tissues. Its shorter half-life (approximately 4-6 hours) requires more frequent administration in research protocols, which can be advantageous for pharmacokinetic studies.
Cardarine (GW-501516)
Like MK-677, Cardarine is not technically a SARM — it is a PPAR-delta (Peroxisome Proliferator-Activated Receptor delta) agonist. It is included here because of its frequent pairing with SARMs in metabolic research. Cardarine activates the PPAR-delta pathway, which plays a critical role in fatty acid oxidation and energy metabolism. Research models have shown significant increases in endurance capacity and shifts in substrate utilization from glucose to lipid oxidation. It is a key compound for studying metabolic flexibility and mitochondrial biogenesis.
SR-9009 (Stenabolic)
SR-9009 is a Rev-ErbA agonist — another compound often categorized with SARMs despite a different mechanism. It modulates the body’s circadian clock proteins (Rev-ErbA alpha and beta), which regulate lipid and glucose metabolism, inflammatory responses, and mitochondrial function. In research models, SR-9009 has demonstrated effects on oxygen consumption, mitochondrial count in skeletal muscle, and circadian rhythm regulation, making it valuable for chronobiology and metabolic research.
YK-11
YK-11 occupies a unique position among research compounds. It functions as both a partial androgen receptor agonist and a myostatin inhibitor. Research has shown that YK-11 induces the expression of follistatin, a protein that inhibits myostatin — a negative regulator of muscle growth. This dual mechanism makes YK-11 particularly interesting for studying the interplay between androgen receptor signaling and the myostatin/follistatin pathway.
SARM Compound Comparison Table
| Compound | Classification | Primary Target | Half-Life | Key Research Focus |
|---|---|---|---|---|
| Ostarine (MK-2866) | Non-steroidal SARM | Androgen Receptor | ~24 hours | Lean mass, bone density |
| LGD-4033 | Non-steroidal SARM | Androgen Receptor | 24-36 hours | Dose-response, muscle tissue |
| RAD-140 | Non-steroidal SARM | Androgen Receptor | ~16 hours | Neuroprotection, selectivity |
| MK-677 | GH Secretagogue | Ghrelin Receptor | ~24 hours | GH/IGF-1 axis |
| Andarine (S-4) | Non-steroidal SARM | Androgen Receptor | 4-6 hours | Partial agonism, bone |
| Cardarine (GW-501516) | PPAR-delta Agonist | PPAR-delta | ~16-24 hours | Fatty acid oxidation, endurance |
| SR-9009 | Rev-ErbA Agonist | Rev-ErbA | ~4 hours | Circadian rhythm, metabolism |
| YK-11 | Steroidal SARM | AR + Myostatin | ~6-10 hours | Myostatin inhibition, follistatin |
Current Research Applications
SARMs are being investigated across a wide range of research domains. The tissue-selective nature of these compounds makes them particularly useful for studying:
Muscle Wasting and Sarcopenia
The most advanced area of SARM research focuses on conditions involving muscle loss. Ostarine (enobosarm) has been studied in clinical trials for cancer-related cachexia and age-related sarcopenia. The ability to stimulate muscle protein synthesis via androgen receptor activation — without the virilizing effects of traditional androgens — addresses a significant gap in available research tools for studying these conditions.
Bone Metabolism
Several SARMs, particularly LGD-4033 and Ostarine, have shown effects on bone mineral density in preclinical models. Research suggests that AR activation in osteoblasts (bone-forming cells) stimulates bone formation, while the tissue selectivity of SARMs avoids the reproductive tissue effects that limit the use of traditional androgens in bone research.
Metabolic Research
Compounds like Cardarine (PPAR-delta agonist) and SR-9009 (Rev-ErbA agonist) are actively used in metabolic research. These compounds allow researchers to study fatty acid oxidation, glucose homeostasis, mitochondrial biogenesis, and energy expenditure pathways. Their distinct mechanisms from true SARMs provide complementary tools for metabolic investigation when used alongside AR-targeting compounds.
Neuroscience
RAD-140 has generated interest in neuroscience research due to observed neuroprotective effects in cell culture and preclinical models. The androgen receptor is expressed in brain tissue, and understanding its role in neuronal health and function is an active area of investigation. RAD-140’s high selectivity ratio makes it a useful tool for isolating AR-mediated effects in neural tissue.
Myostatin Pathway Studies
YK-11’s unique dual mechanism — partial AR agonism combined with myostatin inhibition via follistatin induction — provides researchers with a compound that bridges two important signaling pathways controlling muscle homeostasis. This makes YK-11 valuable for studying the interaction between androgen signaling and the myostatin/activin pathway.
Regulatory Status in the European Union
The regulatory landscape for SARMs in Europe requires careful attention from researchers:
- Not approved for human use — No SARM has received marketing authorization from the European Medicines Agency (EMA) for any clinical indication. SARMs are not classified as medicines, supplements, or food products.
- Research chemical status — SARMs can be legally purchased and possessed for legitimate scientific research purposes in most EU member states. They are classified as research chemicals, not controlled substances, in the majority of European jurisdictions.
- WADA prohibition — SARMs are listed on the World Anti-Doping Agency (WADA) Prohibited List under S1.2 (Other Anabolic Agents). This applies to competitive athletes but does not affect legal research use.
- Country-specific variations — Researchers should verify their specific country’s regulations, as some EU member states may have additional restrictions on the purchase or possession of SARMs for research.
CertaPeptides supplies SARMs exclusively for legitimate research purposes. All products undergo rigorous quality verification — view our testing protocols and Certificate of Analysis verification for full transparency on compound purity and identity.
Quality Considerations for SARM Research
The reliability of any research depends on the quality of materials used. When selecting SARMs for research, critical quality parameters include:
- HPLC purity verification — High-Performance Liquid Chromatography confirms compound identity and purity. Research-grade SARMs should demonstrate a minimum 98% purity.
- Mass spectrometry confirmation — LC-MS/MS analysis confirms the molecular weight and structure of the compound, ensuring it matches the intended chemical entity.
- Certificate of Analysis (COA) — Every batch should be accompanied by a current COA from an independent, accredited laboratory. CertaPeptides provides COAs for all products.
- Proper storage and handling — SARMs should be stored in a cool, dry environment, protected from light. Lyophilized powders are generally more stable than solutions.
Browse our complete SARM research catalog for compounds with verified purity documentation and third-party testing.
Conclusion
SARMs and their associated research compounds (GH secretagogues, PPAR-delta agonists, Rev-ErbA agonists) represent a diverse toolkit for investigating androgen receptor biology, metabolic regulation, and tissue-selective pharmacology. From the well-characterized Ostarine to the mechanistically unique YK-11, each compound offers distinct research value.
As the scientific understanding of these compounds continues to evolve, researchers require access to high-purity, analytically verified materials. CertaPeptides is committed to supporting the research community with independently tested SARMs, comprehensive documentation, and transparent quality standards.
All compounds discussed in this article are supplied strictly for research purposes only. They are not intended for human consumption, therapeutic use, or any application outside of legitimate scientific investigation.